Adjunctive therapy for intractable epilepsy with ethotoin.

Author(s): Biton V, Gates JR, Ritter FJ, Loewenson RB

Affiliation(s): Department of Neurology, University of Minnesota, Minneapolis.

Publication date & source: 1990-07, Epilepsia., 31(4):433-7.

Publication type:

In a retrospective study, records of 46 patients (24 women and 22 men aged 17-51 years; mean 29.2 years), who had been treated with ethotoin (EHN) as adjunctive therapy for control of intractable seizures were reviewed. Overall, approximately 51% of this highly selected patient population had a reduction greater than 50% in overall seizure frequency 1 month after initiation of treatment. This was reduced to approximately 25% for the last 3 months of follow-up (mean follow-up period 10.6 months). Tonic seizure frequency was reduced most dramatically, by greater than 50%, in 60% of patients at 1 month and in 35% of patients for the last 3 months of follow-up. This study suggests that prospective controlled trials of EHN, especially for tonic seizures, are needed.